Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2006

View Archived Issues

ATL-104 lessens mucositis in stem cell transplant patients

PKC-412 demonstrates activity in acute myeloid leukemia, systemic mastocytosis

EntreMed plans IND filing for novel multi-kinase inhibitor

NeurotrophinCell shows potential for prevention of type 1 diabetes

SGX-70393: A novel Bcr-Abl inhibitor with broad efficacy in vitro

Novozymes completes acquisition of GroPep

OSI grants Bristol-Myers Squibb license for DPP-IV inhibitors

AT-2220 begins phase I studies for Pompe disease

Kiadis Pharma formed through merger of Kiadis and Celmed

TNFerade phase II/III trial cleared to continue at interim analysis

Oral cannabinor completes preclinical toxicology and safety pharmacology studies

Forest Laboratories to acquire Cerexa

Novartis works to create new strategic growth platform in human vaccines

Roche files additional Mircera data

Peregrine and Biotecnol to develop novel targeted immunocytokine agents

PATH MVI partners with Sanaria on malaria vaccine

Bradmer discusses with FDA plans for pivotal study of Neuradiab in GBM

Pain perception blocked by SCN9A mutations / News in Context

Roscovitine shows promise in preclinical models of polycystic kidney disease

Novel CRH-R1 antagonist shows potential for the treatment of alcohol abuse

Recent patents impart new therapeutic agents for cancer

Recent CV Therapeutics patents impart novel adenosine A1 receptor agonists for atrial fibrillation

Tysabri sBLA filed for Crohn's disease

Positive opinion in E.U. in GSK's flu pandemic vaccine program

NDA filed for doripenem

European CHMP recommends conditional approval for Prezista in HIV

FDA approval for Bio-E-Gel, to be marketed as Elestrin

FDA approves Cyanokit for cyanide poisoning

ZymoGenetics seeks FDA approval for rhThrombin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...